ReoPro
Links shared publicly online about this topic
Ablynx Initiates Phase II Clinical Trial For ALX-0081
medicalnewstoday.com — “Ablynx [euronext brussels: ablx] announced the initiation of a phase ii study for its anti-thrombotic nanobody® alx-0081, a first-in-class nanobody® targeting von willebrand factor (vwf). ” View full resource at medicalnewstoday.com
Most Recently Shared on September 3, 2009 at 6:14 am By:
MNT Cardiovascular Health News
Ablynx Initiates Phase II Clinical Trial For ALX-0081: Ablynx [Euronext Brussels: ABLX] announced the initiation.. http://bit.ly/1LLtBK
TCT: Last Word Positive on Trial of Bivalirudin (CME/CE) - QualityPoint Technologies
qualitypointtech.net — “WASHINGTON (MedPage Today) -- The final report from the HORIZONS-AMI trial revealed an increasing mortality benefit for ST-elevation MI patients treated with bivalirudin (Angiomax) -- compared with those who received unfractioned heparin plus abciximab (ReoPro) or eptifibatide (Integrelin), according to the trial's lead investigator.” View full resource at qualitypointtech.net
Most Recently Shared on September 27, 2010 at 3:48 pm By:
TCT: Last Word Positive on Trial of Bivalirudin (CME/CE): WASHINGTON (MedPage Today) -- The final report from the ... http://bit.ly/aEZCGI
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Featuring the top 3 experts for this topic
-
MNT Cardiovascular
The latest cardiovascular news published daily. Articles from research centers, universities and prestigious journals.
-
MedicalFeed
Medical news and updates about medical articles and discussion in Google knols and in many medical websites.
Advertisement
